SCHEMBL19639911

SCHEMBL19639911

O=S(=O)(O)c1ccc2c(Br)n[nH]c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
HDAC6 Q9UBN7 1/20 0.39
ALDH1A1 P00352 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
HPGD P15428 2/20 0.39
PDPK1 O15530 1/20 0.39
JAK2 O60674 1/20 0.39
THRB P10828 2/20 0.38
BLM P54132 2/20 0.38
MAP2K7 O14733 2/20 0.38
MAP2K4 P45985 2/20 0.38
MEN1 O00255 1/20 0.38
APEX1 P27695 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
DYRK1A Q13627 4/20 0.37
GSK3B P49841 1/20 0.37
HSD17B10 Q99714 2/20 0.36
CASP6 P55212 2/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19639909 0.87 ALDH1A1 (0.41) PARP1HDAC6ALDH1A1TDP1HPGD
SCHEMBL7530663 0.72 PARP1 (0.63) PARP1HDAC6ALDH1A1TDP1HPGD
SCHEMBL11614800 0.71 JAK2 (0.56) ALDH1A1PDPK1JAK2DYRK1AHSD17B10
SCHEMBL31523324 0.71 MAP2K4 (0.50) PARP1ALDH1A1TDP1HPGDMAP2K4
SCHEMBL18764465 0.69 PDPK1 (0.44) PDPK1JAK2MAP2K4DYRK1AGSK3B
SCHEMBL15529807 0.69 GSK3B (0.48) PARP1ALDH1A1PDPK1JAK2MAP2K4
Hydrochloric Acid SCHEMBL27659735 0.69 JAK2 (0.38) PARP1HDAC6ALDH1A1TDP1HPGD
Hydrochloric Acid SCHEMBL27679753 0.69 JAK2 (0.40) ALDH1A1TDP1HPGDJAK2THRB
SCHEMBL10942866 0.69 ALDH1A1 (0.47) PARP1ALDH1A1TDP1HPGDTHRB
SCHEMBL6394641 0.68 PARP1 (0.61) PARP1HDAC6ALDH1A1TDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-08-25 US disclosed
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-07-04 US disclosed
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) RORA, RORB, RORC PARP1 4865/4885HDAC6 791/4885ALDH1A1 590/4885
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC PARP1 4866/4885HDAC6 786/4885ALDH1A1 587/4885
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC PARP1 4866/4885HDAC6 786/4885ALDH1A1 587/4885
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) RORA, RORB, RORC PARP1 4866/4885HDAC6 786/4885ALDH1A1 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.